Antivirals for COVID-19: A critical review
Open accessThe DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Abstract
No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess the efficacy of these antivirals are ongoing, this review highlights important information including docking and modeling analyses, in vitro studies, as well as results from clinical uses of these antivirals against COVID-19 pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., et al. (2020) · Engineering · doi:10.1016/j.eng.2020.03.007 · Cited by 1,357 · cited 1×
“Ongoing clinical trials in China(119) report favipiravir treatment in patients was significantly correlated with a shorter viral clearance time as compared to untreated patients.(120) Its efficacy has also been assessed in a randomized clinical trial.”
BackgroundRetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · cited 15×
“2) are potential antivirals for SARS-CoV-2.”
BackgroundInfluentialLu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907 · cited 3×
“The process of endocytosis is regulated by AP2-associated protein kinase 1 (AAK1).(39) Therefore, the disruption of AAK1 will not only block the viral entry but also the intracellular viral assembly.”
BackgroundMethodInfluentialA new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 1×
“An in vitro study reported that a combination of remdesivir and chloroquine, an anti-malarial drug, effectively inhibited SARS-CoV-2 growth in Vero E6 cells.(108) Clinical trials are ongoing to assess the efficacy of remdesivir for COVID-19 in the US,(109) Norway,(110) and France.”
BackgroundYang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066 · cited 1×
“In the current pandemic, some available antivirals have been used to treat COVID-19 cases in some countries.(21,22) Since clinical trials to assess the efficacy of available antivirals for COVID-19 are still ongoing, the types”
BackgroundAn interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048 · cited 1×
“2% as of April 13, 2020.(8) SARS-CoV-2 belongs to the family Coronaviridae, subfamily Coronavirinae and genus Betacoronavirus, along with SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV).”
BackgroundStructure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958 · cited 13×
“2) are potential antivirals for SARS-CoV-2.”
BackgroundInfluentialFirst case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030 · cited 1×
“prescribed medication which may alter the pharmacokinetics and plasma concentration of favipiravir.(116,117) This antiviral was associated A.”
BackgroundA Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187 · cited 1×
“In one study, lopinavir-ritonavir treatment was associated with a better outcome but did not significantly accelerate the clinical improvement of severe COVID-19 infection.(74) Although the efficacy of lopinavir has not been assessed for COVID-19, ritonavir-lopinavir combination has been used in treating COVID-19 case…”
BackgroundStructural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735
Coronaviruses: An Overview of Their Replication and Pathogenesis
Fehr, A. R., & Perlman, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,787
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661 · cited 1×
“The virus uses S protein to neutralize antibodies, making it easier to bind to the host receptors.(31) Although the detailed fusion machinery of SARS-CoV-2 is not fully understood, Betacoronavirus mostly use hemagglutinin-esterase (HE) to link to sialic acid on the glycoprotein surface.”
BackgroundThe reproductive number of COVID-19 is higher compared to SARS coronavirus
Liu, Y., Gayle, A. A., Wilder-Smith, A., & Rocklöv, J. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa021 · Cited by 3,192
Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis
Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P., Alvarado-Arnez, L. E., Bonilla-Aldana, D. K., Franco-Paredes, C., Henao-Martinez, A. F., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101623 · Cited by 2,542 · cited 2×
“Rapid assessment of the currently available antiviral drugs to be used for COVID-19 patients is therefore crucial in this time of crisis as well as discovering newer drugs.(5,19) Since the virus hijacks the host system via attaching to and then penetrating the host cells, fol-”
BackgroundMethodSelf-citationTreatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277 · cited 1×
“Apart from antiviral drugs, several promising approaches are also being used to treat COVID-19 such as convalescent plasma, the use of which has shown a reduction in viral load and morbidity of patients.(154,155) IFN-⍺/β(156,157) and IL-6R inhibitor(158,159) have also showed promising effects and are currently being a…”
BackgroundEpidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., Ng, O.-T., Marimuthu, K., Ang, L. W., Mak, T. M., et al. (2020) · JAMA · doi:10.1001/jama.2020.3204 · Cited by 2,059 · cited 1×
“In the current pandemic, some available antivirals have been used to treat COVID-19 cases in some countries.(21,22) Since clinical trials to assess the efficacy of available antivirals for COVID-19 are still ongoing, the types”
BackgroundRole of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645 · cited 1×
“A previous study showed that a specific combination of lopinavirritonavir, known as Kaletra® demonstrated antiviral effects against SARS-CoV both in vitro and in clinical trials.(72) Therefore, the lopinavirritonavir combination is being used as an emergency treatment for COVID-19 patients in some countries(73,74) (Ta…”
MethodCOVID-19: immunopathology and its implications for therapy
Cao, X. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0308-3 · Cited by 1,609
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430 · cited 1×
“Currently, there are more than eighty antiviral drugs available and approved for treating viral infections in humans.(20) Over 50% of”
BackgroundCoronavirus disease 2019 (COVID-19): A literature review
Harapan, H., Itoh, N., Yufika, A., Winardi, W., Keam, S., Te, H., Megawati, D., Hayati, Z., Wagner, A. L., & Mudatsir, M. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.03.019 · Cited by 1,418 · cited 1×
“chest pain, fatigue and myalgia, whereas headache, dizziness, abdominal pain, diarrhea, nausea, and vomiting are less commonly observed.(4) Although most of the SARS-CoV-2 infections are asymptomatic or have”
BackgroundSelf-citationAgostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416 · cited 1×
“characteristics have been studied in SARS-CoV and MERS-CoV infections.(102) It alters functions of viral exonuclease and due to disturbed”
BackgroundA Novel Coronavirus Emerging in China — Key Questions for Impact Assessment
Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D., & de Wit, E. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2000929 · Cited by 1,415
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
Matsuyama, S., Nao, N., Shirato, K., Kawase, M., Saito, S., Takayama, I., Nagata, N., Sekizuka, T., Katoh, H., Kato, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002589117 · Cited by 1,411 · cited 1×
“It downregulates expression of SARS-CoV-2 spike (S) protein to prevent surface fusion and thereby blocks the cellular entry of the virus.(51,52) A previous study found that camostat mesylate prevented SARS-CoV entry into human bronchial epithelial cells.”
BackgroundProbable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak
Zhang, T., Wu, Q., & Zhang, Z. (2020) · Current Biology · doi:10.1016/j.cub.2020.03.022 · Cited by 1,397 · cited 1×
“Its genome contains open reading frames 1a and 1b (ORF1a and ORF1b) genes that produce two polyproteins (pp), called pp1a and pp1b, that help in hijacking host ribosomes for viral translation process.(36,37) These polyproteins are then cleaved by main protease (M) and papain-like protease (P) to produce several non-st…”
BackgroundDiscovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,390
Potential interventions for novel coronavirus in China: A systematic review
Zhang, L., & Liu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25707 · Cited by 1,348 · cited 1×
“treating pneumonia caused due to SARS-CoV-2 in COVID-19 patients.(49,50) Camostat mesylate Camostat mesylate – a serine protease inhibitor – is another candidate drug that targets the fusion step in viruses.”
BackgroundXia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0305-x · Cited by 1,343
Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia
Chu, D. K. W., Pan, Y., Cheng, S. M. S., Hui, K. P. Y., Krishnan, P., Liu, Y., Ng, D. Y. M., Wan, C. K. C., Yang, P., Wang, Q., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa029 · Cited by 1,278 · cited 2×
“However, studies have reported the use of a combination of oseltamivir with ganciclovir and lopinavir/ritonavir to treat COVID-19 patients in Wuhan.132,133 A computational study also supported synergistic effects of oseltamivir-lopinavir-ritonavir combination against SARS-CoV-2.”
BackgroundCOVID-19: combining antiviral and anti-inflammatory treatments
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117 · cited 1×
“may not be effective in reducing the viral infectivity at tolerable doses.(54) Therapeutic use of baricitinib is associated with the occurrence of neutropenia, lymphocytopenia, and viral reactivation.”
BackgroundDevaux, C. A., Rolain, J.-M., Colson, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105938 · Cited by 1,099 · cited 2×
“Although the detailed fusion machinery of SARS-CoV-2 is not fully understood, Betacoronavirus mostly use hemagglutinin-esterase (HE) to link to sialic acid on the glycoprotein surface.(32,33) These fusion steps could be inhibited using fusion inhibitors (Fig.”
BackgroundFavipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070 · cited 3×
“Favipiravir (Avigan) Favipiravir (T705), a purine (guanine) nucleotide analog is a deri- vative of pyrazine carboxamide (6‐fluoro‐3‐hydroxy‐2‐pyrazinecarboxamide) and an RdRp inhibitor.112 It was initially developed against influenza but attracted attention for COVID-19 treatment due to its large spectrum antiviral pr…”
BackgroundStructural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants
Tahir ul Qamar, M., Alqahtani, S. M., Alamri, M. A., & Chen, L.-L. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.03.009 · Cited by 1,032 · cited 1×
“Recently, potential anti-viral phytochemicals that have activity against the 3CL of SARS-CoV-2 were identified while screening medicinal plant library and the top antiviral candidates identified can be further evaluated using in vitro studies.(97)”
BackgroundThe epidemiology, diagnosis and treatment of COVID-19
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., & Li, Y. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105955 · Cited by 1,014
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Choy, K.-T., Wong, A. Y.-L., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P.-H., Huang, X., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104786 · Cited by 922
The convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903 · cited 1×
“Apart from antiviral drugs, several promising approaches are also being used to treat COVID-19 such as convalescent plasma, the use of which has shown a reduction in viral load and morbidity of patients.(154,155) IFN-⍺/β(156,157) and IL-6R inhibitor(158,159) have also showed promising effects and are currently being a…”
BackgroundFavipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852 · cited 1×
“Its efficacy has also been assessed in a randomized clinical trial.(121) Favipiravir is currently being used for COVID19 treatment in Japan(79) and Indonesia(122) (Table 1).”
Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ac120.013056 · Cited by 850 · cited 1×
“sults have shown antiviral potential against bat and human coronaviruses in primary epithelial and lung cell culture systems.(100,101)”
BackgroundChen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683296 · Cited by 849
Structural insights into coronavirus entry
(2019) · Advances in Virus Research · doi:10.1016/bs.aivir.2019.08.002 · Cited by 769 · cited 1×
“viral entry into the host cells through cellular receptor angiotensinconverting enzyme 2 (ACE2).(12,13) Similar to other viruses, SARS-CoV-2”
BackgroundMahase, E. (2020) · BMJ · doi:10.1136/bmj.m641 · Cited by 720
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117477 · Cited by 715 · cited 1×
“ribavirin is a promising candidate drug for COVID-19 treatment and can be administered either by intra-venous route or orally.(128) Ribavirin and”
Oral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711 · cited 1×
“Oseltamivir – a neuraminidase inhibitor – is effective in preventing influenza(130) and was successful in treating influenza in children.(131)”
BackgroundLiu, Z., Xiao, X., Wei, X., Li, J., Yang, J., Tan, H., Zhu, J., Zhang, Q., Wu, J., & Liu, L. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25726 · Cited by 691
From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
Hilgenfeld, R. (2014) · The FEBS Journal · doi:10.1111/febs.12936 · Cited by 660 · cited 1×
“These polyproteins are then cleaved by main protease (M) and papain-like protease (P) to produce several non-structural proteins.(38) Beside M and P, 3C-like cysteine protease (3CL) has also been suggested to exist in SARS-CoV-2 based on”
BackgroundLim, J., Jeon, S., Shin, H.-Y., Kim, M. J., Seong, Y. M., Lee, W. J., Choe, K.-W., Kang, Y. M., Lee, B., & Park, S.-J. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e79 · Cited by 636
Subissi, L., Posthuma, C. C., Collet, A., Zevenhoven-Dobbe, J. C., Gorbalenya, A. E., Decroly, E., Snijder, E. J., Canard, B., & Imbert, I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323705111 · Cited by 595
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Shiraki, K., & Daikoku, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107512 · Cited by 573 · cited 1×
“vative of pyrazine carboxamide (6‐fluoro‐3‐hydroxy‐2‐pyrazinecarboxamide) and an RdRp inhibitor.(112) It was initially developed against”
BackgroundFantini, J., Di Scala, C., Chahinian, H., & Yahi, N. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105960 · Cited by 561 · cited 1×
“compared to the S protein of SARS-CoV-2 and therefore due to competitive binding to sialic acid and gangliosides present on the surface of the target cell, it prevents attachment and entry of the virus.(150) In addition to the antiviral activity, chloroquine possesses anti-inflammatory”
ResultMechanisms of action of ribavirin against distinct viruses
Graci, J. D., & Cameron, C. E. (2006) · Reviews in Medical Virology · doi:10.1002/rmv.483 · Cited by 549 · cited 3×
“Along with this, ribavirin inhibits the function of inosine monophosphate dehydrogenase enzyme to prevent the production of guanosine and hence promotes degradation of viral RNA.(125) If at all any replication would with ribavirin intake, probability of arbitrary mutation in the RNA is immense, leading to loss of viru…”
BackgroundThe SARS coronavirus nucleocapsid protein – Forms and functions
Chang, C.-K., Hou, M.-H., Chang, C.-F., Hsiao, C.-D., & Huang, T.-H. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2013.12.009 · Cited by 529
Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F., & Matsuyama, S. (2012) · Journal of Virology · doi:10.1128/jvi.00094-12 · Cited by 515
Brown, A. J., Won, J. J., Graham, R. L., Dinnon, K. H., Sims, A. C., Feng, J. Y., Cihlar, T., Denison, M. R., Baric, R. S., & Sheahan, T. P. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104541 · Cited by 510 · cited 1×
“sults have shown antiviral potential against bat and human coronaviruses in primary epithelial and lung cell culture systems.(100,101)”
BackgroundYan, C., Cui, J., Huang, L., Du, B., Chen, L., Xue, G., Li, S., Zhang, W., Zhao, L., Sun, Y., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.04.001 · Cited by 507
Deng, L., Li, C., Zeng, Q., Liu, X., Li, X., Zhang, H., Hong, Z., & Xia, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.002 · Cited by 505 · cited 1×
“Combination of ritonavir-lopinavir and umifenovir also substantially halted the progression of lung damage too.(76) In one study, lopinavir-ritonavir treatment was associated with a better outcome but did not significantly accelerate the clinical improvement of severe COVID-19 infection.”
ResultWang, J. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00179 · Cited by 498 · cited 13×
“2) are potential antivirals for SARS-CoV-2.”
BackgroundInfluentialGriffin, S. D. C., Beales, L. P., Clarke, D. S., Worsfold, O., Evans, S. D., Jaeger, J., Harris, M. P. G., & Rowlands, D. J. (2003) · FEBS Letters · doi:10.1016/s0014-5793(02)03851-6 · Cited by 497 · cited 1×
“A previous study showed that amantadine could block the p7 protein of HCV that is crucial in forming ion channels in host cell membranes.(138) A report in 1973 showed that amantadine had a potent effect against Coronavirus 229E in vitro,(139) and later a report also showed that amantadine was able to block protein-mem…”
MethodOestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., & Günther, S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.02.014 · Cited by 493 · cited 1×
“with rapid clearance of Ebola virus in an animal model.(118) Ongoing clinical trials in China(119) report favipiravir treatment in patients was significantly correlated with a shorter viral clearance time as compared to untreated patients.”
BackgroundNafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
Hoffmann, M., Schroeder, S., Kleine-Weber, H., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00754-20 · Cited by 486 · cited 2×
“Another serine protease inhibitor, nafamostat mesylate was found to possess 15-fold higher efficiency in inhibiting the entry of SARS-CoV-2 virus into host cells.(64) Hence due to its more potent antiviral activity and favorable safety profile, nafamostat mesylate can be considered as a better alternative to camostat…”
BackgroundCoronavirus puts drug repurposing on the fast track
Harrison, C. (2020) · Nature Biotechnology · doi:10.1038/d41587-020-00003-1 · Cited by 470 · cited 3×
“tochrome P-450 inhibitors like ritonavir or cobicistat and in vitro studies have demonstrated their replication inhibitory effect against SARS-CoV2.(66) A clinical trial in Thailand is underway to assess the effectiveness of darunavir combination with other antivirals and hydroxychloroquine for COVID-19 patients.”
BackgroundPotential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines
Liu, X., & Wang, X.-J. (2020) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.02.001 · Cited by 464
Welliver, R. (2001) · JAMA · doi:10.1001/jama.285.6.748 · Cited by 463
The dependence of viral RNA replication on co-opted host factors
Nagy, P. D., & Pogany, J. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2692 · Cited by 449 · cited 1×
“The negative-strand RNA is then used by viral replicase to synthesize new positive RNA molecules to process another translation and replication step to form the genome of the newest viral particles.(44) In SARS-CoV, topoisomerase III-beta mediates this process.”
BackgroundCompounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
Martinez, M. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00399-20 · Cited by 444 · cited 13×
“2) are potential antivirals for SARS-CoV-2.”
ResultInfluentialStructural basis of influenza virus fusion inhibition by the antiviral drug Arbidol
Kadam, R. U., & Wilson, I. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617020114 · Cited by 435 · cited 1×
“the hemagglutinin envelope glycoprotein (HA) in the fusion machinery of influenza virus.(56) A recent study reported that umifenovir mono-”
BackgroundArbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
Zhu, Z. H., Lu, Z., Xu, T., Chen, C., Yang, G., Zha, T. A., Lu, J., & Xue, Y. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.060 · Cited by 427 · cited 6×
“Lopinavir-ritonavir alone or in combination with interferon (INF)-β – an inflammation regulator molecule – have been listed by WHO as options for “solidarity” clinical trial for COVID-19.”
BackgroundInfluentialMuralidharan, N., Sakthivel, R., Velmurugan, D., & Gromiha, M. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1752802 · Cited by 415 · cited 13×
“2) are potential antivirals for SARS-CoV-2.”
BackgroundInfluentialStructural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA
Ferron, F., Subissi, L., Silveira De Morais, A. T., Le, N. T. T., Sevajol, M., Gluais, L., Decroly, E., Vonrhein, C., Bricogne, G., Canard, B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718806115 · Cited by 404
Remdesivir as a possible therapeutic option for the COVID-19
Al-Tawfiq, J. A., Al-Homoud, A. H., & Memish, Z. A. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101615 · Cited by 367
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
Khalili, J. S., Zhu, H., Mak, N. S. A., Yan, Y., & Zhu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25798 · Cited by 359 · cited 2×
“If at all any replication would with ribavirin intake, probability of arbitrary mutation in the RNA is immense, leading to loss of virulence in progeny viruses.(124) Its efficacy in treating SARS-CoV-2 patients is being tested in clinical trials in Hong Kong.”
BackgroundShannon, A., Le, N. T.-T., Selisko, B., Eydoux, C., Alvarez, K., Guillemot, J.-C., Decroly, E., Peersen, O., Ferron, F., & Canard, B. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104793 · Cited by 352 · cited 1×
“A non-structural protein, called nsp12 forms a replication and transcription complex called RNA-dependent RNA polymerase (RdRp).(41) In SARS-CoV, nsp12 associates with its cofactor (nsp7 and nsp8)(42,43) and this protein complex produces a complementary negative-sense RNA using the original positive RNA as a template.”
BackgroundLiu, F., Xu, A., Zhang, Y., Xuan, W., Yan, T., Pan, K., Yu, W., & Zhang, J. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.013 · Cited by 346 · cited 1×
“Administration of lopinavir as an emergency drug in China increased the eosinophil count among COVID-19 patients.(70) In an in silico study, a combination of lopinavir and ritonavir – both used as HIV”
BackgroundKhan, R. J., Jha, R. K., Amera, G. M., Jain, M., Singh, E., Pathak, A., Singh, R. P., Muthukumaran, J., & Singh, A. K. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1753577 · Cited by 343 · cited 13×
“2) are potential antivirals for SARS-CoV-2.”
BackgroundInfluentialArguments in favour of remdesivir for treating SARS-CoV-2 infections
Ko, W.-C., Rolain, J.-M., Lee, N.-Y., Chen, P.-L., Huang, C.-T., Lee, P.-I., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105933 · Cited by 316 · cited 1×
“Designated as GS-5734, remdesivir is a nucleotide analog possessing a wide spectrum of antiviral properties against majority of the single stranded RNA viruses like coronaviruses (including MERS-CoV and SARS-CoV-2) Lassa fever virus, Junin virus, Ebola-Marburg virus, respiratory syncytial virus, Nipah virus and Hendra…”
BackgroundCoronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding
Klumperman, J., Locker, J. K., Meijer, A., Horzinek, M. C., Geuze, H. J., & Rottier, P. J. (1994) · Journal of Virology · doi:10.1128/jvi.68.10.6523-6534.1994 · Cited by 314 · cited 1×
“region through the Golgi apparatus and vesicles as a mature virus and released from the cells to infect other cells.(48)”
BackgroundDrug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
Ghosh, A. K., Brindisi, M., Shahabi, D., Chapman, M. E., & Mesecar, A. D. (2020) · ChemMedChem · doi:10.1002/cmdc.202000223 · Cited by 306
Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Gasmi, A., Noor, S., Tippairote, T., Dadar, M., Menzel, A., & Bjørklund, G. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108409 · Cited by 305 · cited 1×
“It downregulates expression of SARS-CoV-2 spike (S) protein to prevent surface fusion and thereby blocks the cellular entry of the virus.(51,52) A previous study found that camostat mesylate prevented SARS-CoV entry into human bronchial epithelial cells.”
BackgroundHall, D. C., & Ji, H.-F. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101646 · Cited by 296
Zeng, Q., Langereis, M. A., van Vliet, A. L. W., Huizinga, E. G., & de Groot, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800502105 · Cited by 288
Nal, B., Chan, C., Kien, F., Siu, L., Tse, J., Chu, K., Kam, J., Staropoli, I., Crescenzo-Chaigne, B., Escriou, N., et al. (2005) · Journal of General Virology · doi:10.1099/vir.0.80671-0 · Cited by 272
The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence
Chatterjee, P., Nagi, N., Agarwal, A., Das, B., Banerjee, S., Sarkar, S., Gupta, N., & Gangakhedkar, R. R. (2020) · Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_519_20 · Cited by 258
Solidarity” clinical trial for COVID-19 treatments
Mendez, C. M. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 257
Amirian, E. S., & Levy, J. K. (2020) · One Health · doi:10.1016/j.onehlt.2020.100128 · Cited by 234
Use of antiviral drugs to reduce COVID-19 transmission
Mitjà, O., & Clotet, B. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30114-5 · Cited by 230 · cited 1×
“with SARS-CoV-2 infected individuals.(153)”
Fintelman-Rodrigues, N., Sacramento, C. Q., Ribeiro Lima, C., Souza da Silva, F., Ferreira, A. C., Mattos, M., de Freitas, C. S., Cardoso Soares, V., da Silva Gomes Dias, S., Temerozo, J. R., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00825-20 · Cited by 179
Nicastri, E., Petrosillo, N., Ascoli Bartoli, T., Lepore, L., Mondi, A., Palmieri, F., D’Offizi, G., Marchioni, L., Murachelli, S., Ippolito, G., et al. (2020) · Infectious Disease Reports · doi:10.4081/idr.2020.8543 · Cited by 177 · cited 2×
“Darunavir, an anti-HIV drug, has been recommended for COVID-19 treatment in Italy.(88) It is used in a combined regimen along with cy-”
MethodRabaan, A. A., Al-Ahmed, S. H., Sah, R., Tiwari, R., Yatoo, M. I., Patel, S. K., Pathak, M., Malik, Y. S., Dhama, K., Singh, K. P., et al. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-020-00384-w · Cited by 177
Self-citationKhamitov, R. A., Loginova, S. I., Николаевна, Щ. В., Borisevich, S. V., Maksimov, V. A., & Shuster, A. M. (2008) · PubMed · Cited by 171
Quirós-Roldán, E., Biasiotto, G., Magro, P., & Zanella, I. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104904 · Cited by 164 · cited 2×
“structural configuration of cell receptors or by competitively binding to the cellular receptors.(149) It can amend the glycosylation of ACE-2 cellular receptors needed for SARS-CoV-2 entry.”
Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective
Malik, Y. S., Kumar, N., Sircar, S., Kaushik, R., Bhat, S., Dhama, K., Gupta, P., Goyal, K., Singh, M. P., Ghoshal, U., et al. (2020) · Pathogens · doi:10.3390/pathogens9070519 · Cited by 164
Self-citationMomekov, G., & Momekova, D. B. (2020) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2020.1775118 · Cited by 161
Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal
Sah, R., Rodriguez-Morales, A. J., Jha, R., Chu, D. K. W., Gu, H., Peiris, M. J. S., Bastola, A., Lal, B. K., Ojha, H. C., Rabaan, A. A., et al. (2020) · Microbiology Resource Announcements · doi:10.1128/mra.00169-20 · Cited by 157 · cited 1×
“Its genome contains open reading frames 1a and 1b (ORF1a and ORF1b) genes that produce two polyproteins (pp), called pp1a and pp1b, that help in hijacking host ribosomes for viral translation process.(36,37) These polyproteins are then cleaved by main protease (M) and papain-like protease (P) to produce several non-st…”
BackgroundNoor, M. A., Flint, O. P., Maa, J.-F., & Parker, R. A. (2006) · AIDS · doi:10.1097/01.aids.0000244200.11006.55 · Cited by 155 · cited 1×
“A previous study on HIV infected patients showed that a combination of atazanavir with ritonavir improved glucose uptake and lipid parameters and decreased fasting glucose more effectively as compared to lopinavir-ritonavir combination.(92,93) This suggests that atazanavir might be an alternative for lopinavir when co…”
BackgroundAmantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment
Smieszek, S. P., Przychodzen, B. P., & Polymeropoulos, M. H. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106004 · Cited by 143
Patrì, A., & Fabbrocini, G. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.017 · Cited by 140 · cited 1×
“synergistic effect due to the inhibition of both, viral entry as well as viral replication.(144) However pharmacokinetic analysis indicates that higher dosage is required for achieving the antiviral activity.”
BackgroundNelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro
Yamamoto, N., Matsuyama, S., Hoshino, T., & Yamamoto, N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.06.026476 · Cited by 136 · cited 1×
“Another study showed that saquinavir, indinavir, amprenavir and nelfinavir inhibit SARS-CoV-2 in vitro(95) with nelfinavir showing the best inhibition in comparison with others.(95) Saquinavir has been used in treatment of COVID-19 patients in Singapore (Table 1).”
ResultFenner and White's Medical Virology
(2016) · Elsevier eBooks · doi:10.1016/c2009-0-01817-0 · Cited by 136
Parents’ hesitancy towards vaccination in Indonesia: A cross-sectional study in Indonesia
Yufika, A., Wagner, A. L., Nawawi, Y. S., Wahyuniati, N., Anwar, S., Yusri, F., Haryanti, N., Wijayanti, N. P., Rizal, R., Fitriani, D., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.01.072 · Cited by 128
Self-citationNuclear trafficking of proteins from RNA viruses: Potential target for antivirals?
Caly, L., Wagstaff, K. M., & Jans, D. A. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.06.008 · Cited by 121 · cited 3×
“mectin against several RNA viruses is mediated by the inhibition of importin α/β1-mediated nuclear import.(143) SARS-CoV-2 being an RNA”
BackgroundInfluentialChang, Y., Tung, Y., Lee, K.-H., Chen, T.-F., Hsiao, Y., Chang, H.-C., Hsieh, T.-T., Su, C.-H., Wang, S.-S., Yu, J.-Y., et al. (2020) · Preprints.org · doi:10.20944/preprints202002.0242.v1 · Cited by 114
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
Praveen, D., Puvvada, R. C., & Aanandhi, M. V. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105967 · Cited by 103 · cited 2×
“Since SARSCoV-2 infected patients have a lower absolute lymphocyte count, use of baricitinib may increase the incidence of co-infection.(55) Further studies are required to analyze the risk-benefit ratio as well as the clinical”
BackgroundPotential of heparin and nafamostat combination therapy for COVID‐19
Asakura, H., & Ogawa, H. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14858 · Cited by 102 · cited 1×
“will be further beneficial in managing the DIC with enhanced fibrinolysis seen in COVID-19 patients.(65)”
BackgroundChang, Y., Tung, Y., Lee, K.-H., Chen, T.-F., Hsiao, Y., Chang, H.-C., Hsieh, T.-T., Su, C.-H., Wang, S.-S., Yu, J.-Y., et al. (2020) · Preprints.org · doi:10.20944/preprints202002.0242.v2 · Cited by 97
Keam, S., Megawati, D., Patel, S. K., Tiwari, R., Dhama, K., & Harapan, H. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2123 · Cited by 92 · cited 1×
“The disease severity, in part, seems to be associated with dysregulation of the host immune response.(6) The basic reproductive number (R0) of SARS-CoV-2 is higher than that of SARS Coronavirus (SARS-CoV)(7) with a mortality rate of up to 6.”
BackgroundSelf-citationReceptor-binding domain as a target for developing SARS vaccines.
Zhu, X., Liu, Q., Du, L., Lu, L., & Jiang, S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.06.06 · Cited by 80 · cited 1×
“viral entry into the host cells through cellular receptor angiotensinconverting enzyme 2 (ACE2).(12,13) Similar to other viruses, SARS-CoV-2”
BackgroundLongitudinal CT Findings in COVID-19 Pneumonia: Case Presenting Organizing Pneumonia Pattern
Wu, Y., Xie, Y., & Wang, X. (2020) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.2020200031 · Cited by 73
Recent progress in the discovery of inhibitors targeting coronavirus proteases
Wang, H., Xue, S., Yang, H., & Chen, C. (2016) · Virologica Sinica · doi:10.1007/s12250-015-3711-3 · Cited by 61
Stanley, T. L., JOY, T. R., Hadigan, C. M., Liebau, J., Makimura, H., Chen, C. Y., Thomas, B. J., Weise, S. B., Robbins, G. K., & Grinspoon, S. K. (2009) · AIDS · doi:10.1097/qad.0b013e32832ba904 · Cited by 55 · cited 1×
“A previous study on HIV infected patients showed that a combination of atazanavir with ritonavir improved glucose uptake and lipid parameters and decreased fasting glucose more effectively as compared to lopinavir-ritonavir combination.(92,93) This suggests that atazanavir might be an alternative for lopinavir when co…”
BackgroundLi, Z., Wang, Y., Zhu, J., Zhang, Y., Zhang, W., Zhou, M., Luo, C., Li, Z. J., Cai, B., Gui, S., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.007 · Cited by 51 · cited 1×
“SARSCoV-2 is transmitted among humans mainly via respiratory droplets, although it may also follow an airborne transmission mode.(24,25) The virus enters the host cells through two pathways, either via endosomes or plasma membrane fusion.”
BackgroundCOVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help
Lentini, G., Cavalluzzi, M. M., & Habtemariam, S. (2020) · Molecules · doi:10.3390/molecules25081834 · Cited by 45 · cited 1×
“Before the large-scale recommendation of off-label use, the potential of chloroquine to cause detrimental cardiac effects must be considered.(152) Currently a randomized controlled trial has been registered to evaluate the prophylactic”
BackgroundChatterjee, S. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3562504 · Cited by 31
Patiyal, S., Kaur, D., Kaur, H., Sharma, N., Dhall, A., Sahai, S., Agrawal, P., Maryam, L., Arora, C., & Raghava, G. P. S. (2020) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2020.0035 · Cited by 30
Calling all coronavirus researchers: keep sharing, stay open
(2020) · Nature · doi:10.1038/d41586-020-00307-x · Cited by 26
Human Plasma Protein Corona of Aβ Amyloid and Its Impact on Islet Amyloid Polypeptide Cross-Seeding
Nandakumar, A., Xing, Y., Aranha, R., Faridi, A., Käkinen, A., Javed, I., Koppel, K., Pilkington, E. H., Purcell, A. W., Davis, T. P., et al. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.9b01650 · Cited by 25 · cited 1×
“SARSCoV-2 is transmitted among humans mainly via respiratory droplets, although it may also follow an airborne transmission mode.(24,25) The virus enters the host cells through two pathways, either via endosomes or plasma membrane fusion.”
Background“Amantadine disrupts lysosomal gene expression; potential therapy for COVID19”Preprint
Smieszek, S. P., Przychodzen, B. P., & Polymeropoulos, M. H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.05.026187 · Cited by 20
Chiodini, P., Arenare, L., Piccirillo, M. C., Perrone, F., & Gallo, C. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100665 · Cited by 17
Is GSK3β a molecular target of chloroquine treatment against COVID-19?
Embi, M. N., Ganesan, N., & Sidek, H. M. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.03010 · Cited by 13
Pascual, M. R. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2004.00746 · Cited by 11 · cited 1×
“This is because the list of structural and non-structural proteins of SARS-CoV-2 is similar to those in these two viruses.(14) A non-structural protein, called nsp12 forms a replication and transcription complex called RNA-dependent RNA polymerase (RdRp).”
Background
Cited by
A review: Mechanism of action of antiviral drugs
Kausar, S., Said Khan, F., Ishaq Mujeeb Ur Rehman, M., Akram, M., Riaz, M., Rasool, G., Hamid Khan, A., Saleem, I., Shamim, S., & Malik, A. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211002621 · Cited by 429
Myths and conspiracy theories on vaccines and COVID-19: Potential effect on global vaccine refusals
Ullah, I., Khan, K. S., Tahir, M. J., Ahmed, A., & Harapan, H. (2021) · Vacunas · doi:10.1016/j.vacun.2021.01.001 · Cited by 302
Self-citationMorales-Paredes, C. A., Rodríguez-Díaz, J. M., & Boluda-Botella, N. (2022) · Science of The Total Environment · doi:10.1016/j.scitotenv.2021.152691 · Cited by 197
Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials
Selvaraj, V., Finn, A., Lal, A., Khan, M. S., Dapaah-Afriyie, K., & Carino, G. P. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101489 · Cited by 101
Karki, N., Verma, N., Trozzi, F., Tao, P., Kraka, E., & Zoltowski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041573 · Cited by 43
Metadata
- Authors
- Frediansyah, A., Tiwari, R., Sharun, K., Dhama, K., & Harapan, H.
- Venue
- Clinical Epidemiology and Global Health
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 9
- Pages
- 90-98
- ISSN
- 2213-3984 (ISSN-L)
- OpenAlex
- W3046074789
- Cited by
- 185
- References
- 123
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.